Clinical Pharmacokinetics

, Volume 37, Supplement 2, pp 25–32 | Cite as

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol

Original Research Article



The pharmacokinetic profiles of cilostazol and its metabolites following a single oral dose of cilostazol 100mg were compared between individuals with impaired and normal liver function.


The study was conducted as a single-centre, open-label, single dose pharmacokinetic and tolerability trial.

Study Participants

12 patients with impaired and compensated liver function were compared with 12 volunteers with normal liver function. Participants in each group were matched for gender, age and weight. Of the 12 patients with hepatic impairment examined in this study, 10 had mild impairment (Child-Pugh class A) and 2 had moderate impairment (Child-Pugh class B).

Main Outcome Measures

Blood and urine were collected up to 144 hours after drug administration. Pharmacokinetics were determined by noncompartmental methods.


Protein binding did not differ between the groups (95.2% healthy volunteers, 94.6% hepatically impaired patients). Mean ± SD unbound oral clearance of cilostazol decreased by 8.6% because of hepatic impairment (3380 ± 1400 ml/min in healthy volunteers, 3260 ± 2030 ml/min in hepatically impaired patients). Total urinary excretion of metabolites was significantly higher in healthy volunteers (26 vs 17% of dose). Overall, the pharmacokinetics of cilostazol and its metabolites, OPC-13213 and OPC-13015, were not substantially different in those with mild and moderate hepatic disease compared with values in healthy volunteers. Except for terminal-phase disposition half-life and apparent terminal-phase volume of distribution for cilostazol, the ratios of geometric means of pharmacokinetic parameters for plasma cilostazol, OPC-13213 and OPC-13015 in those with hepatic impairment versus healthy volunteers were close to 100%.


Based on the results of the pharmacokinetic analysis, dose adjustment in patients with mild hepatic impairment is not necessary. However, caution should be exercised when cilostazol is administered to patients with moderate or severe hepatic impairment.


Adis International Limited Hepatic Impairment Cilostazol Normal Liver Function Severe Hepatic Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35(7A): 1144–9.PubMedGoogle Scholar
  2. 2.
    Kohriyama T, Tanaka E, Katayama S, et al. Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase-assessment of its effect on coagulation and fibrinolytic parameters. Rinsho Shinkeigaku 1994; 34(8): 771–6.PubMedGoogle Scholar
  3. 3.
    Uchikawa T, Murakami T, Furukawa H. Effects of the antiplatelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992; 42(3): 322–4.PubMedGoogle Scholar
  4. 4.
    Okuda Y, Mizutani M, Ikegami T, et al. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic nephropathy. Arzneimittelforschung 1992; 42(4): 540–2.PubMedGoogle Scholar
  5. 5.
    Tsuchikane E, Katoh O, Sumitsuji S, et al. Impact of cilostazol on intimai proliferation following directional coronary atherectomy: a prospective randomized trial. J Am Coll Cardiol 1997; 29(2 Suppl. A): 397A.Google Scholar
  6. 6.
    Suehiro A, Sugimoto Y, Masuda H, et al. A study of the effects of cilostazol on platelet function and serum lipids in patients with diabetes mellitus. Curr Ther Res 1993; 54(5): 553–61.CrossRefGoogle Scholar
  7. 7.
    Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. ArteriosclerThromb Vasc Biol 1998; 18(12): 1942–7.CrossRefGoogle Scholar
  8. 8.
    Bramer SL, Tata PNV, Mallikaarjun S, et al. Disposition of 14C-cilostazol after single dose administration to healthy human subjects [abstract No. 3452]. American Association of Pharmaceutical Scientists Annual Meeting; 1997 Nov 2–6; Boston. Pharm Res 1997; 14 Suppl. 11: S612.Google Scholar
  9. 9.
    Abbas R, Chow CP, Browder NJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. In press.Google Scholar
  10. 10.
    Fu CJ, Tata PNV, Bramer SL. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high performance liquid chromatography. J Chromatogr B Biomed Sci App 1999; 728(2): 251–62.CrossRefGoogle Scholar
  11. 11.
    Tata PNV, Fu CJ, Bramer SL. Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. J Liq Chromatogr Relat Tech. In press.Google Scholar
  12. 12.
    Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Jusko WJ, Schentag JJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992; 2: 1–43.Google Scholar
  13. 13.
    Gerok W. Hepatology. Baltimore; Urban & Schwarzenberg, 1987; 534–7.Google Scholar
  14. 14.
    Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams and Wilkins, 1995.Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Otsuka America Pharmaceutical, Inc.RockvilleUSA

Personalised recommendations